The decision on systemic treatment is based on several clinicopathological features such as ER, PR, and HER-2 status as well as the stage of cancer, tumor size, nodal involvement, menopausal status, age and health status of the patient [7]. This evidence concerns the gene ERBB2 and neoplasm.